| Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne (NCT07756957) | Sanofi Pasteur, a Sanofi Company | 2026-10-30 |
| A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years (NCT07536048) | Sanofi Pasteur, a Sanofi Company | 2026-04-20 |
| Phase 3 Single Arm, Open Study on vYF in Adults (NCT07222059) | Sanofi Pasteur, a Sanofi Company | 2025-10-23 |
| Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne (NCT07013747) | Sanofi Pasteur, a Sanofi Company | 2025-07-03 |
| Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents (NCT06838000) | Sanofi Pasteur, a Sanofi Company | 2025-02-28 |
| Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea (NCT06793826) | Sanofi Pasteur, a Sanofi Company | 2025-01-17 |
| Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants (NCT06824207) | Sanofi Pasteur, a Sanofi Company | 2025-01-13 |
| A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older (NCT06744205) | Sanofi Pasteur, a Sanofi Company | 2025-01-06 |
| Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (NCT06736041) | Sanofi Pasteur, a Sanofi Company | 2024-12-18 |
| Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older (NCT06727058) | Sanofi Pasteur, a Sanofi Company | 2024-12-09 |
| A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (NCT06705140) | Sanofi Pasteur, a Sanofi Company | 2024-11-25 |
| Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older (NCT06686654) | Sanofi Pasteur, a Sanofi Company | 2024-11-11 |
| Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (NCT06647407) | Sanofi Pasteur, a Sanofi Company | 2024-11-05 |
| Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (NCT06641180) | Sanofi Pasteur, a Sanofi Company | 2024-11-04 |
| Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants (NCT06800885) | Sanofi Pasteur, a Sanofi Company | 2024-10-22 |
| Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age (NCT06582056) | Sanofi Pasteur, a Sanofi Company | 2024-10-09 |
| Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years (NCT06583031) | Sanofi Pasteur, a Sanofi Company | 2024-10-09 |
| Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older (NCT06604767) | Sanofi Pasteur, a Sanofi Company | 2024-09-17 |
| Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older (NCT06507553) | Sanofi Pasteur, a Sanofi Company | 2024-08-12 |
| Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (NCT06397768) | Sanofi Pasteur, a Sanofi Company | 2024-05-13 |
| Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne (NCT06316297) | Sanofi Pasteur, a Sanofi Company | 2024-04-05 |
| Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older (NCT06251024) | Sanofi Pasteur, a Sanofi Company | 2024-04-02 |
| BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study) (NCT06325332) | Sanofi Pasteur, a Sanofi Company | 2024-04-01 |
| A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above (NCT06361875) | Sanofi Pasteur, a Sanofi Company | 2024-04-01 |
| Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers (NCT06284915) | Sanofi Pasteur, a Sanofi Company | 2024-03-19 |
| Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (NCT06252285) | Sanofi Pasteur, a Sanofi Company | 2024-02-06 |
| Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older (NCT06237296) | Sanofi Pasteur, a Sanofi Company | 2024-01-23 |
| Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam (NCT06228586) | Sanofi Pasteur, a Sanofi Company | 2024-01-18 |
| Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate (NCT06134648) | Sanofi Pasteur, a Sanofi Company | 2023-11-01 |
| Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (NCT06128733) | Sanofi Pasteur, a Sanofi Company | 2023-10-31 |
| Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy (NCT05929651) | Sanofi Pasteur, a Sanofi Company | 2023-09-07 |
| Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers (NCT05964582) | Sanofi Pasteur, a Sanofi Company | 2023-07-11 |
| Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (NCT05829356) | Sanofi Pasteur, a Sanofi Company | 2023-04-12 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (NCT05794230) | Sanofi Pasteur, a Sanofi Company | 2023-03-27 |
| Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA) (NCT05687279) | Sanofi Pasteur, a Sanofi Company | 2023-02-06 |
| Dengvaxia US Pregnancy Registry (NCT04486638) | Sanofi Pasteur, a Sanofi Company | 2023-01-01 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older (NCT05650554) | Sanofi Pasteur, a Sanofi Company | 2022-12-12 |
| Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older (NCT05624606) | Sanofi Pasteur, a Sanofi Company | 2022-11-28 |
| Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older (NCT05639894) | Sanofi Pasteur, a Sanofi Company | 2022-11-17 |
| Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (NCT05513391) | Sanofi Pasteur, a Sanofi Company | 2022-11-10 |
| Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older (NCT05608005) | Sanofi Pasteur, a Sanofi Company | 2022-11-03 |
| Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. (NCT05513053) | Sanofi Pasteur, a Sanofi Company | 2022-10-27 |
| Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23 (NCT05568979) | Sanofi Pasteur, a Sanofi Company | 2022-10-06 |
| Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers (NCT04936685) | Sanofi Pasteur, a Sanofi Company | 2022-08-23 |
| Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life (NCT05437510) | Sanofi Pasteur, a Sanofi Company | 2022-08-08 |
| Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older (NCT05426174) | Sanofi Pasteur, a Sanofi Company | 2022-06-09 |
| Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older (NCT06118151) | Sanofi Pasteur, a Sanofi Company | 2022-04-11 |
| Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea (NCT05144945) | Sanofi Pasteur, a Sanofi Company | 2021-12-07 |
| Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22 (NCT05078060) | Sanofi Pasteur, a Sanofi Company | 2021-10-12 |
| Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia (NCT05011123) | Sanofi Pasteur, a Sanofi Company | 2021-10-07 |
| Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris (NCT05131373) | Sanofi Pasteur, a Sanofi Company | 2021-09-28 |
| Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively (NCT05050318) | Sanofi Pasteur, a Sanofi Company | 2021-09-08 |
| Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine (NCT04969276) | Sanofi Pasteur, a Sanofi Company | 2021-07-16 |
| Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA (NCT04942210) | Sanofi Pasteur, a Sanofi Company | 2021-07-01 |
| Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States (NCT05040802) | Sanofi Pasteur, a Sanofi Company | 2021-06-02 |
| Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (NCT04904549) | Sanofi Pasteur, a Sanofi Company | 2021-05-26 |
| Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (NCT04825223) | Sanofi Pasteur, a Sanofi Company | 2021-03-29 |
| Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (NCT04490018) | Sanofi Pasteur, a Sanofi Company | 2021-03-16 |
| Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (NCT04798027) | Sanofi Pasteur, a Sanofi Company | 2021-03-12 |
| Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (NCT04762680) | Sanofi Pasteur, a Sanofi Company | 2021-02-24 |
| Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa (NCT04300192) | Sanofi Pasteur, a Sanofi Company | 2021-01-27 |
| Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (NCT04537234) | Sanofi Pasteur, a Sanofi Company | 2020-11-10 |
| Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (NCT04498832) | Sanofi Pasteur, a Sanofi Company | 2020-10-21 |
| Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland (NCT04594551) | Sanofi Pasteur, a Sanofi Company | 2020-10-11 |
| Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (NCT04491877) | Sanofi Pasteur, a Sanofi Company | 2020-09-17 |
| Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively (NCT04551677) | Sanofi Pasteur, a Sanofi Company | 2020-09-16 |
| Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (NCT04544267) | Sanofi Pasteur, a Sanofi Company | 2020-09-15 |
| Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older (NCT04537208) | Sanofi Pasteur, a Sanofi Company | 2020-09-03 |
| Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (NCT04478084) | Sanofi Pasteur, a Sanofi Company | 2020-08-04 |
| Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (NCT04451954) | Sanofi Pasteur, a Sanofi Company | 2020-07-02 |
| Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (NCT04429295) | Sanofi Pasteur, a Sanofi Company | 2020-06-28 |
| Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (NCT04398706) | Sanofi Pasteur, a Sanofi Company | 2020-05-22 |
| Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 (NCT04222985) | Sanofi Pasteur, a Sanofi Company | 2020-02-18 |
| Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia (NCT04113330) | Sanofi Pasteur, a Sanofi Company | 2020-01-31 |
| Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults (NCT04142086) | Sanofi Pasteur, a Sanofi Company | 2020-01-15 |
| Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age (NCT04210349) | Sanofi Pasteur, a Sanofi Company | 2020-01-09 |
| Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update (NCT04170140) | Sanofi Pasteur, a Sanofi Company | 2020-01-07 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (NCT04143061) | Sanofi Pasteur, a Sanofi Company | 2019-12-30 |
| Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age (NCT04144179) | Sanofi Pasteur, a Sanofi Company | 2019-11-06 |
| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults (NCT02741128) | Sanofi Pasteur, a Sanofi Company | 2019-11-06 |
| Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older (NCT04137887) | Sanofi Pasteur, a Sanofi Company | 2019-11-04 |
| Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (NCT04127786) | Sanofi Pasteur, a Sanofi Company | 2019-10-21 |
| Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 (NCT04142242) | Sanofi Pasteur, a Sanofi Company | 2019-10-04 |
| Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (NCT04109222) | Sanofi Pasteur, a Sanofi Company | 2019-09-30 |
| Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4) (NCT04084769) | Sanofi Pasteur, a Sanofi Company | 2019-09-03 |
| Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (NCT03965962) | Sanofi Pasteur, a Sanofi Company | 2019-07-01 |
| A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada (NCT03958799) | Sanofi Pasteur, a Sanofi Company | 2019-06-26 |
| Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (NCT03869866) | Sanofi Pasteur, a Sanofi Company | 2019-04-09 |
| Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine (NCT03430089) | Sanofi Pasteur, a Sanofi Company | 2019-02-22 |
| Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam (NCT03765437) | Sanofi Pasteur, a Sanofi Company | 2019-01-15 |
| Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (NCT03547271) | Sanofi Pasteur, a Sanofi Company | 2018-12-14 |
| Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years) (NCT06698198) | Sanofi Pasteur, a Sanofi Company | 2018-12-03 |
| Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (NCT03630705) | Sanofi Pasteur, a Sanofi Company | 2018-10-17 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (NCT03632720) | Sanofi Pasteur, a Sanofi Company | 2018-10-10 |
| Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (NCT03698279) | Sanofi Pasteur, a Sanofi Company | 2018-10-09 |
| Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (NCT03691610) | Sanofi Pasteur, a Sanofi Company | 2018-10-04 |
| Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year (NCT03700242) | Sanofi Pasteur, a Sanofi Company | 2018-09-26 |
| Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (NCT03673462) | Sanofi Pasteur, a Sanofi Company | 2018-09-17 |
| Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring (NCT04460781) | Sanofi Pasteur, a Sanofi Company | 2018-09-17 |
| Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (NCT03617523) | Sanofi Pasteur, a Sanofi Company | 2018-09-10 |